Large Scale Intermediates

Complementing our commercial manufacturing and packaging services, we provide a range of commercial storage and distribution solutions for solid oral dosage forms and sterile biopharmaceuticals, for both niche / orphan drug products and large scale commercial market volumes.

Utilising our bespoke E...

Almac’s peptide and protein technology offering is a key component within our suite of services.  We offer a complete range of peptide and protein services from catalogue products through to GMP manufacture from early phase to commercial launch.  We have a proven track record in high quality supply,...

Almac’s experienced formulation scientists can develop a range of oral dose formulations for early stage clinical trials.

With both non-GMP and GMP facilities, flexible and efficient solutions are provided to develop a fit-for-purpose formulation for your early phase clinical trial.
...

Pharmaceutical Product Launch and Distribution
Having successfully partnered in the launch of 15 significant orphan and niche drug products into the EU market over the last 3 years, Almac is the industry leader for Pharmaceutical Product Launch and Distribution.

...

Almac’s Physical Sciences groups’ comprehensive range of services and expertise will help strengthen the success of your product.

Identifying and consistently producing a drug in its optimal physical form is vital to any successful drug development programme. It also avoids the need for bridging to...

Serialisation and Track & Trace
Addressing evolving global serialisation legislation, Almac’s expert multi-disciplinary serialisation team lead the way in supporting clients in developing their serialisation strategies to GS1 standards.

...

Neoantigen derived vaccines have become a major new strategy within oncology as researchers look to harness the body’s own immune system to fight cancer. The treatment platform is completely individualized. A patient’s tumor is biopsied and genetically sequenced to identify the epitope mutations which are pre...

Enabling Confidence and Security in the Supply Chain

Specialising in solid oral dosage forms, Almac has the technical experience and knowledge to develop robust formulations and manufacturing processes.

We have assisted many of our clients in the development of both immediate and modif...

Almac’s strength in API development and manufacture is proven by being the partner of choice for many pharma and biotech companies seeking integrated drug development solutions from molecule to market.

Our technical expertise and extensive facilities enable us to offer integrated API contract manuf...

QC and analytical support, including method development and validation, method transfer and radiolabelling stability studies

With our extensive experience in the synthesis and analysis of stable and 14C isotope labelled compounds – from drug discovery thr...

From our state-of-the-art analytical laboratories in the UK and US, our highly skilled analysts deliver comprehensive solutions to support drug substance (API) and drug product development programs. Analytical and microbiological testing solutions for clinical and commercial drug product supply are also provi...

Biocatalysis Solutions:  Biocatalysts are essential tools in chemical synthesis, particularly in the synthesis of pharmaceutical and fine chemical targets. As highly selective catalysts, they offer a direct and simple way to synthesise complex achiral and chiral compounds. The application of biocata...

The CDMO will raise its headcount to 8,000 across its 19 global facilities amid increased demand for services

Almac Group invites you to find out more about our wide range of end to end innovative solutions including API Manufacture, Analytical Services, Formulation Development, Clinical Trial Supply Management Commercial-scale Manufacture and Pack capabilities.

The CDMO plans to roll out the ISO 45001 and ISO 14001 certification throughout multiple sites worldwide

Almac Sciences offers services including API development & manufacture, radiolabelling, biocatalysis solutions, peptides & protein technology, pre-formulation, solid state and analytical services.

The company's £0.5 million investment in mass spectrometry support accelerates biologics development and approval

Almac Pharma Services offers early and late phase pharmaceutical development. Its expertise also includes pharmaceutical product launch & distribution, commercial drug product manufacture, commercial packaging, serialisation and commercial storage & distribution.

Athlone, Ireland - 15 September 2020 –  Almac Sciences, a member of Almac Group, has announced the expansion of its existing suite of analytical solutions to include biologics testing.

Almac Group is proud of its global reputation for excellence, delivering expertise right across the drug development lifecycle and offering a tailored solution to each client. We will be exceptional, always.

Audubon, PA, 16 April 2018 – Almac Group, the global contract pharmaceutical development and manufacturing organisation, is pleased to announce that it has expanded its US commercial packaging capabilities at its Audubon, PA facility.

Almac Sciences, a member of the Almac Group, has announced the expansion of its existing suite of analytical solutions to include biologics testing. 

This new offering follows the announcement of the company’s expansion of its Irish laboratory in 2019 and from which Almac Sciences now provides a comprehensive range of flexible pharmaceutical testing services to support clients’ drug development programs adhering to industry regulations including FDA, EMA and PMDA, under GMP standards

Almac’s new services include GMP lot release and stability testing to support clients’ drug substance and drug product programs for both novel biologics and biosimilars; fit-for-purpose analytical method development / phase-appropriate method validation; raw material testing for microbial and mammalian expression systems that comply with pharmacopeial requirements and clients’ specifications. 

Almac Group, the global contract development and manufacturing organization, is delighted to announce that they have brought online a second stream for High Throughput GMP Peptide manufacturing.

Almac Group, the global contract development and manufacturing organization, is delighted to announce it has won awards in all core categories for 2019 for excellence in Quality, Reliability, Capabilities, Expertise, Compatibility, and Service.

Further to Almac Group’s recent announcement regarding expansion of its global analytical services capabilities, the organization is delighted to announce additional expansion plans at its Athlone facility.

Almac Sciences, a member of the Almac Group, today announced the appointment of Dr Sheryl Foster to the position of Vice President of Quality, reporting to Managing Director & President, Dr Stephen Barr.

Almac Sciences, a member of the Almac Group, has announced a collaboration with Science Exchange, the world’s leading R&D Services Management company. The partnership will offer online access to Almac’s integrated services from development through commercial scale production of active pharmaceutical ingredients to clients worldwide.